Mutant prevention concentration:: a new tool for choosing treatment in nontuberculous mycobacterial infections

被引:10
作者
Rodríguez, JC [1 ]
Cebrián, L [1 ]
López, M [1 ]
Ruiz, M [1 ]
Royo, G [1 ]
机构
[1] Univ Miguel Hernandez, Hosp Gen Univ Elche, Microbiol Sect, Elche 03203, Alicante, Spain
关键词
mutant prevention concentration; fluoroquinolones; linezolid; macrolides; nontuberculous mycobacteria;
D O I
10.1016/j.ijantimicag.2004.03.026
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
The mutant prevention concentration (MPC) of fluoroquinolones, linezolid, rifabutin, rifampicin and macrolides was determined in 16 nontuberculous Mycobacterium species in order to compare the incidence of resistant mutant occurrence for different antibiotics. Linezolid showed good activity against Mycobacterium gordonae and Mycobacterium kansasii. Rifabutin had a lower MPC values than rifampicin. The fluoroquinolones were more active against M. gordonae and Mycobacterium chelonae. Clarithromycin had better MPC values than azithromycin but its intracellular concentration was high. Mutant prevention concentration may help to establish abetter clinico-microbiological correlation, the sub-populations of drug-resistant micro-organisms may be detected by that method. It is still important to administer correct drug doses, to use combined therapies and to find new drugs that are useful in the treatment of these infections. (C) 2004 Elsevier B.V. and the International Society of Chemotherapy. All rights reserved.
引用
收藏
页码:352 / 356
页数:5
相关论文
共 39 条
[1]  
Apseloff G, 1998, J CLIN PHARMACOL, V38, P830
[2]   Susceptibility to mycobacterial infections: the importance of host genetics [J].
Bellamy, R .
GENES AND IMMUNITY, 2003, 4 (01) :4-11
[3]  
BERGER C, 1996, PEDIATRICS, V28, P383
[4]   Emergence of Mycobacterium avium populations resistant to macrolides during experimental chemotherapy [J].
Bermudez, LE ;
Petrofsky, M ;
Kolonoski, P ;
Young, LS .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1998, 42 (01) :180-183
[5]  
Bordet AL, 1997, ANN DERMATOL VENER, V124, P251
[6]   Successful treatment of disseminated Mycobacterium chelonae infection with linezolid [J].
Brown-Elliot, BA ;
Wallace, RJ ;
Blinkhorn, R ;
Crist, CJ ;
Mann, LB .
CLINICAL INFECTIOUS DISEASES, 2001, 33 (08) :1433-1434
[7]   The value of in vitro drug activity and pharmacokinetics in predicting the effectiveness of antimycobacterial therapy: A critical review [J].
Burman, WJ .
AMERICAN JOURNAL OF THE MEDICAL SCIENCES, 1997, 313 (06) :355-363
[8]   Diagnosis, differentiating colonization, infection, and disease [J].
Catanzaro, A .
CLINICS IN CHEST MEDICINE, 2002, 23 (03) :599-+
[9]   Activity of clarithromycin alone and in combination in a murine model of Mycobacterium kansasii infection [J].
Cynamon, MH ;
Elliott, SA ;
DeStefano, MS ;
Yeo, AET .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2003, 52 (02) :306-307
[10]   Comparative distribution of azithromycin in lung tissue of patients given oral daily doses of 500 and 1000 mg [J].
Danesi, R ;
Lupetti, A ;
Barbara, C ;
Ghelardi, E ;
Chella, A ;
Malizia, T ;
Senesi, S ;
Angeletti, CA ;
Del Tacca, M ;
Campa, M .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2003, 51 (04) :939-945